Search Results: 100% Pass Quiz High Pass-Rate Juniper - JN0-281 - Data Center, Associate (JNCIA-DC) New Braindumps Ebook 🐍 Open ➽ www.pdfvce.com 🢪 enter ➡ JN0-281 ️⬅️ and obtain a free download 🔮Valid Exam JN0-281 Book

AusperBio Announces First-in-Human Dosing of AHB-137, an Antisense Oligonucleotide Drug Candidate for the Treatment of Chronic Hepatitis B

03/14/2023

Excerpt from the Press Release: SAN FRANCISCO, March 9, 2023 /PRNewswire/ — Ausper Biopharma Co., Ltd. and AusperBio Therapeutic, Inc. (Together AusperBio) today announced the completion of the first cohort dosing in a Phase 1 clinical trial evaluating AHB–137 in adult healthy volunteers and chronic hepatitis B (CHB) patients in New Zealand. AHB-137 is a…

Read More

Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study

08/10/2021

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced today that the Company has received approval for a Clinical Trial Application (CTA) from…

Read More

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

03/08/2022

Excerpt from the Press Release: SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’s health services agency, allowing the CardiAMP® Heart Failure Trial to…

Read More

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

09/06/2023

Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced the first patient has been dosed in the Phase 1 study of FHD-286 in combination with decitabine…

Read More

Ontario Institute for Cancer Research announces funding for sixteen studies that support early detection of cancer, the development of new diagnostics to guide therapy and improved treatment options for patients

12/06/2021

Funding provides $16 million in support for Ontario cancer research Excerpt from the Press Release: December 2, 2021—Toronto—Today the Ontario Institute for Cancer Research (OICR) announced funding for 16 studies as part of the Institute’s new Clinical Translation Pathway (CTP). These awards support pre-clinical research and new clinical trials that have a focus on early…

Read More

Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

06/22/2022

Investigational New Drug Application Submitted by Omega Represents the First Epigenomic Controller in a New Class of Programmable mRNA Therapeutics Excerpt from the Press Release: CAMBRIDGE, Mass., June 15, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug…

Read More

Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavio

08/26/2022

The dataset will be publicly available for a Kaggle competition presented at NeurIPS 2022 hosted by Open Problems in Single-Cell Analysis in collaboration with Chan Zuckerberg Initiative, Chan Zuckerberg Biohub, Yale University, and Helmholtz Munich Excerpt from the Press Release: SOMERVILLE, Mass.–(BUSINESS WIRE)–Cellarity, a life sciences company founded by Flagship Pioneering to transform the way…

Read More

Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

01/12/2023

Excerpt from the Press Release: PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) — Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator (PoNS®) into the hands of qualified Americans with multiple sclerosis (MS) at a…

Read More

Onconova Therapeutics Announces The Initial Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of ON 123300

05/24/2021

Excerpt from the Press Release: NEWTOWN, Pa., May 21, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the U.S. Phase 1 clinical trial of ON 123300, the Company’s proprietary, novel…

Read More

World first: focused ultrasound opens blood-brain barrier for delivery of therapeutic in Parkinson’s disease

10/31/2020

Excerpt from the Article: In a groundbreaking, world-first clinical trial, a team of researchers from Sunnybrook Health Sciences Centre and University Health Network are using focused ultrasound technology to deliver a therapeutic directly to affected brain regions in patients with Parkinson’s disease (PD). Parkinson’s affects more than 6 million people around the world. It is…

Read More